Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prism Medico and Pharmacy Ltd's board, which met on 13 February 2026, approved the unaudited standalone financial results for the quarter ended 31 December 2025 along with the Limited Review Report from the auditors. For Q3 FY26, revenue from operations was Rs 7.10 lakhs, sharply lower than Rs 50.23 lakhs in the previous quarter, and the company reported a small net loss of Rs 1.34 lakhs versus a loss of Rs 8.48 lakhs in Q2 FY26. On a nine-month basis, however, the company swung to a net profit of Rs 55.91 lakhs compared with a net loss of Rs 4.87 lakhs in the same period last year, helped by lower overall expenses. Paid-up equity share capital stood at Rs 606.34 lakhs and other equity at Rs 958.85 lakhs, with EPS of Rs (0.0002) for the quarter. The company operates in a single segment and figures are prepared under Ind AS.
The sharp sequential drop in quarterly revenue is a concern, but the year-to-date swing into profit provides some relief. For shareholders, this is a routine quarterly results update with no major corporate action, so the immediate stock impact is likely limited.